We recently published a list of the 10 Best High Short Interest Stocks to Buy Now. In this article, we are going to take a ...

The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635 (c) ...

H.C. Wainwright reiterates Cytokinetics (CYTK) as a top pick after Bristol-Myers (BMY) announced that the Phase 3 ODYSSEY-HCM clinical trial ...

Merida Biosciences has emerged from Third Rock Ventures with $121 million in first-round financing for a pipeline of drugs ...

Cytokinetics (CYTK) stock rises and rival Edgewise (EWTX) stock drops as the latter posts mixed Phase 2 trial data for its heart disorder therapy EDG-7500. Read more here.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to ...

J&J also raised its full-year revenue guidance to include sales of the psychiatric drug Caplyta, which the company got from ...

California Public Employees Retirement System trimmed its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – ...

Franklin Resources Inc. boosted its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.7% in the fourth quarter, HoldingsChannel reports. The firm owned 545,813 shares of ...

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive ...

Aficamten, a cardiac myosin inhibitor (CMI), is the cornerstone of Cytokinetics' near-term prospects. The drug has shown promising results in clinical trials, demonstrating significant gradient ...

Cytokinetics (CYTK) shares rallied 5.4% in the last trading session to close at $45.43. This move can be attributable to notable volume with a higher number of shares being traded than in a ...